May 20, 2013
AstraZeneca K.K. (AZ) and Bristol-Myers K.K. (BMKK) on May 16 launched Bydureon SC Injection 2 mg (exenatide), a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. According to the companies, it is the world’s first once-weekly...read more